Evidence map›Paper›PMID 41868876›Full record

ArticleAnnals of gastroenterology

Expert recommendations regarding the use of fecal calprotectin in daily clinical practice: statements of a taskforce process from the Hellenic Group for the Study of Inflammatory Bowel Disease (EOMIFNE).

Giorgos Bamias, Smaragdi Fessatou, Christina Kapizioni, Konstantina Kitsou, Georgios Kokkotis, Afroditi Kourti, Panagiotis Markopoulos, Eleni Orfanoudaki, Spyros Siakavellas, Maria Tzouvala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giorgos BamiasGI Unit, 3 Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens (Giorgos Bamias, Georgios Kokkotis).
Smaragdi FessatouDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, 3 Department of Paediatrics, Attikon University General Hospital, National and Kapodistrian University of Athens (Smaragdi Fessatou, Afroditi Kourti).
Christina KapizioniDepartment of Gastroenterology, Athens Medical Center (Christina Kapizioni).
Konstantina KitsouNational and Kapodistrian University of Athens (Konstantina Kitsou).
Georgios KokkotisGI Unit, 3 Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens (Giorgos Bamias, Georgios Kokkotis).
Afroditi KourtiDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, 3 Department of Paediatrics, Attikon University General Hospital, National and Kapodistrian University of Athens (Smaragdi Fessatou, Afroditi Kourti).
Panagiotis MarkopoulosDepartment of Gastroenterology, "Metaxa" Memoriam Hospital (Panagiotis Markopoulos).
Eleni OrfanoudakiDepartment of Gastroenterology, General Hospital of Chania, Crete (Eleni Orfanoudaki).
Spyros SiakavellasLiver-GI Unit, 2 Academic Department of Internal Medicine, "Hippocration" General Hospital of Athens, National and Kapodistrian University of Athens (Spyros Siakavellas).
Maria TzouvalaDepartment of Gastroenterology, "Agios Panteleimon" General Hospital, Nikaia, Piraeus, (Maria Tzouvala), Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fecal calprotectin (FC) has become an indispensable tool in everyday clinical practice for the diagnosis and management of inflammatory bowel disease (IBD). Nonetheless, specific and clear recommendations for its use are scarce. On behalf of the Hellenic Group for the Study of IBD (EOMIFNE), a group of experts have formulated 18 statements with the aim to provide evidence for the best use of FC and offer practical guidance in common clinical scenarios. Statements address issues for the proper application of FC measurement in the diagnostic workup of patients with gastrointestinal symptoms, and as a screening tool for the management of established IBD, including pediatric patients. Thus, the present manuscript aims to propose a standardized approach for the optimal use of FC in patient care, also taking into account non-medical concerns.

Indexed as

EOMIFNEFecal calprotectinguidelinesinflammatory bowel disease

Identifiers

PMID41868876
PMCPMC13004819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.